Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 14Breast Neoplasms 9Thyroid Nodule 4Thyroid Neoplasms 4Lymphoma 4Disease 4Head and Neck Neoplasms 3Uveal Melanoma 2Neoplasm Metastasis 2Melanoma 2Gastrointestinal Stromal Tumors 2Uveal Neoplasms 1Sarcoma, Ewing 1Sarcoidosis 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Peutz-Jeghers Syndrome 1Pancreatitis, Chronic 1Pancreatic Cyst 1Neoplastic Cells, Circulating 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1Lung Neoplasms 1Iris Neoplasms 1Focus: Breast Cancer With Axillary Node Metastasis 1Fanconi Anemia, Complementation Group D1 1Esophagus 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 16Temozolomide 13Vincristine 10Irinotecan 8Melphalan 7Doxorubicin 7Topotecan 6Granulocyte Colony-Stimulating Factor 6Busulfan 6fludarabine 5cabozantinib 5Etoposide 5Drug Therapy 5liposomal doxorubicin 4Sirolimus 4Ifosfamide 4Filgrastim 4regorafenib 3pegfilgrastim 3irinotecan sucrosofate 3fludarabine phosphate 3Zoledronic Acid 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cisplatin 3Bone Marrow Transplantation 3Albumin-Bound Paclitaxel 3pegylated granulocyte colony-stimulating factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Ewing × Biopsy, Fine-Needle × Clear all
NCT05042934 2022-02-10

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡